Natpara: Phase III data

The double-blind, U.S. Phase III RELAY trial in 46 patients showed that 18% of patients receiving 25 µg Natpara and 25% of patients receiving 50 µg Natpara achieved the primary endpoint of a reduction in daily oral calcium

Read the full 384 word article

How to gain access

Continue reading with a
two-week free trial.